Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction

Metabolism: Clinical and Experimental

Volumn 57, Issue SUPL.2, 2008, Pages

  VanItallie, Theodore B ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGRICULTURAL CHEMICAL; FUNGICIDE; HERBICIDE; IRON; PESTICIDE;

AGING; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; HEAD INJURY; HEREDITY; HUMAN; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGE FACTORS; AGED; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; PARKINSON DISEASE; RISK FACTORS;

EID: 51649123733     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.07.015     Document Type: Review

References (41)

1. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
2. Muller-Hocker J. Mitochondria and ageing. Brain Pathol 2 (1992) 149-158
3. Finsterer J. Mitochondiopathies. Eur J Neurol 11 (2006) 163-186
4. Semenza G.L. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor-1. Biochem J 405 (2007) 1-9
5. Martin L.J. Mitochondriopathy in Parkinson's disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65 (2006) 1103-1110
6. Lang A.E., and Lozano A.M. Parkinson's disease. Part 1. N Engl J Med 339 (1998) 1044-1053
7. Langston J.W., Ballard P., and Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
8. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36 (1985) 2503-2508
9. Mann V.M., Cooper J.M., Krige D., et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 (1992) 333-342
10. Rango M., Bonifati C., and Bresolin N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorous magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26 (2006) 283-290
11. Diederich N.J., Raman R., Leurgans S., and Goetz C.G. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 59 (2002) 1249-1252
12. Parker Jr. W.D., Parks J.K., and Swendlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 1189 (2008) 215-218
13. Papapetropoulos S., Adi N., Ellul J., Argyriou A.A., and Chroni E. A prospective study of familial versus sporadic Parkinson's disease. Neurodegener Dis 4 (2007) 424-427
14. Zorzon M., Capus L., Pellegrino A., Cazzato G., and Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in northeast Italy. Ann Neurol Scand 105 (2002) 77-82
15. Bender A., Krishnan K.J., Morris C.M., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38 (2006) 515-517
16. Mizuno Y., Hattori N., Yoshino H., et al. Progress in familial Parkinson's disease. J Neural Transm Suppl (2006) 191-204
17. Moghal S., Rajput A.H., D'Arcy C., and Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 13 (1994) 175-178
18. Zhang Z.X., and Roman G.C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12 (1993) 195-208
19. Ishihara L., and Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113 (2006) 211-220
20. Davie C.A., Pirtosek Z., Barker G.J., et al. Magnetic resonance spectroscopy study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 58 (1995) 688-691
21. Bower J.H., Maraganore D.M., Peterson B.J., et al. Head trauma preceding PD: a case-control study. Neurology 60 (2003) 1610-1615
22. Goldman S.M., Tanner C.M., Oakes D., et al. Head injury and Parkinson's disease risk in twins. Ann Neurol 60 (2006) 65-72
23. Brighina L., Frigerio R., Schneider N.K., et al. (alpha)-Synuclein, pesticides, and Parkinson disease. A case-control study. Neurology (2008) (Electronic publication ahead of print)
24. Firestone J.A., Smith-Weller T., Franklin G., Swanson P., Longstreth Jr. W.T., and Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 62 (2005) 91-95
25. Bové J., Prous D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
26. Cochemé H.M., and Murphy M.P. Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem 283 (2008) 1786-1798
27. Sherer T.B., Richardson J.R., Testa C.M., et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 100 (2007) 1469-1479
28. Barlow B.K., Richfield E.K., Cory-Slechta D.A., and Thiruchelvam M. A fetal risk factor for Parkinson's disease. Dev Neurosci 26 (2004) 11-23
29. Gerlach M., Double K.L., Youdin M.B., and Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 70 (2006) 123-142
30. Jellinger K.A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14 (1999) 114-140
31. Hu G., Pekka J., Bidel S., Antikainen R., and Tuomilehto J. Type 2 diabetes and risk of Parkinson's disease. Diabetes Care 30 (2007) 842-847
32. Hu G., Jousilahti P., Nissinen A., Antikainen R., Kivipelto M., and Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 67 (2006) 1955-1959
33. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150 (2007) 963-976
34. Bower J.H., Maraganore D.M., Peterson B.J., Ahlskog J., and Rocca W.A. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67 (2006) 494-496
35. Tzourio C., Rocca W.A., Breteler M.M.B., et al. Smoking and Parkinson's disease: an age-dependent risk effect?. Neurology 49 (1997) 1267-1272
36. Ascherio A., Zhang S.M., Hernán M.A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50 (2001) 56-63
37. Weisskopf M., O'Reilly E., Chen H., Schwarzchild M., and Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166 (2007) 561-567
38. Chen H., Zhang S.M., Schwarzschild M.A., Hernan M.A., and Ascherio A. Physical activity and risk of Parkinson disease. Neurology 64 (2005) 664-669
39. de Lau L.M., Giesbergen P.C., de Rijk M.C., et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63 (2004) 1240-1244
40. Gibb W.R.G., and Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (1988) 745-752
41. Kraytsberg Y., Kudryaviseva E., McKee A.C., et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38 (2006) 518-520